Novithera SAS: Exploiting kinases for the development of small-molecule cancer immuno-therapeutics




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Novithera SAS: Exploiting kinases for the development of small-molecule cancer immuno-therapeutics
Released on: October 24, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Novithera, a joint venture between NovAliX and ProQinase.
  • Summary
  • Participants
  • Company
Novithera, a joint venture between NovAliX and ProQinase. Luc Van Hijfte, President & Chief Executive Officer at Novithera, discusses with Fintan Walton, CEO of PharmaVentures, its mission to exploit kinases for the development of small-molecule cancer immuno-therapeutics.
Luc Van Hijfte, President & Chief Executive Officer at Novithera
Novithera, a joint venture between NovAliX and ProQinase, has been founded with the mission to exploit kinases for the development of small-molecule cancer immuno-therapeutics